KEROS THERAPEUTICS IN

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 12 2021 09:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

13 12 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

22 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

15 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

11 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

08 11 2021 08:00:02 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

04 11 2021 09:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

04 11 2021 09:00:02 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

04 10 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

02 9 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

05 8 2021 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

02 8 2021 09:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

22 6 2021 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

11 6 2021 08:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference

27 5 2021 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

25 5 2021 08:00:05 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

14 5 2021 08:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

12 5 2021 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

06 5 2021 16:01:02 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

25 3 2021 08:00:01 提供 Nasdaq GlobeNewswire